Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.17 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
81 82 Next >
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. 
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Is Novo Nordisk an Undervalued Stock to Buy Now?
Via The Motley Fool
What's Going on With Novo Nordisk Stock?
Via The Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets. 
Via Benzinga
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60. 
Via Benzinga
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches. 
Via Benzinga
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
President-Elect Trump Poses Challenge To U.S. Tech Sales
Technology sales in the U.S. could reach a record level in 2025, if tariffs don't spoil the party, a tech futurist said at CES 2025. 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives. 
Via Benzinga
Exposures Product Safety
3 Trends To Watch
Hot topics for 2025 and why. 
Via Talk Markets
Topics Stocks / Equities
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from licensed professionals to ensure safety. 
Via Benzinga
4 Top Stocks to Buy in January
Here are four stocks to buy now that could offer investors upside in the short and long terms. 
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation. 
Via Benzinga
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Shares of Novo Nordisk are in free fall following lackluster results from a new clinical trial. 
Via The Motley Fool
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead. 
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering. 
Via Chartmill
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Top Growth Stocks for 2025
All 10 have had a good 2024, but I believe the best is yet to come. 
Via The Motley Fool
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
The world's richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.